Medical sector’s Kadmon’s (NYSE:KDMN) Buy rating Reiterated by HC Wainwright

0
44
Loan, Accidents and Disasters, Accountancy, Finance, Piggy Bank

Kadmon (NYSE:KDMN)‘s stock had its Buy rating Reiterated by analysts at HC Wainwright in a research report issued to clients and investors. A price-to-earnings ratio of #N/A, market cap of 822.5M and a beta of 1.47.  Kadmon has a twelve month low $1.93 of  and a twelve month high of $5.50.

Shares of Kadmon traded down -$0.06 on Monday, reaching $5.14. 850118 shares of the stock traded hands, compared to its average volume of 3330290. Shares of Kadmon at mid-way of the day on Monday were at $5.14. The firm’s 50 day moving average is $$4.56 and its 200 day moving average is $4.05.Kadmon  has a 12 month low of $5.02 and a 12 month high of $5.50. While on yearly highs and lows, Kadmon’s today has traded high as $5.32 and has touched $5.02 on the downward trend. See More Analyst Rating at: RATING

Kadmon (NYSE:KDMN) Moving Average Technical Analysis

5 day Moving Average is $5.19 And 5 day price change is $0.49 (10.63%)  with average volume for 5 day average is 3,056,973. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $4.74 and 20 day price change is $0.54 (11.84%) and average 20 day moving volume is 2,547,153. 50 day moving average is $4.56  and 50 day price change is $0.70 ( 15.91%)  and with average volume for 50 days is : 2,558,633. 200 day moving average is $4.05  and 200 day price change is $2.30 (82.14%)  and with average volume for 200 days is : 1,985,896.

See More Analyst Rating at: RATING

Kadmon Earnings and What to expect: 

Kadmon last issued its earnings data on May 7th, 2020. The reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.05. The company earned $6.74 million during the quarter, compared to analyst estimates of $0.38 million. Kadmon has generated ($0.74) earnings per share over the last year. Kadmon has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 3rd, 2020 based off prior year’s report dates.

Earnings for Kadmon are expected to grow in the coming year, from ($0.61) to $0.34 per share. The P/E ratio of Kadmon is -7.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Kadmon is -7.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Kadmon has a P/B Ratio of 5.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 2.95%
  • On 3/13/2020 CEO Harlan Waksal Buy 16,000 at average share price of $2.93 which equates to $46,880.00 in money value.
  • On 3/12/2020 Director Cynthia Schwalm Buy 31,000 at average price of  $3.24 with total value of : Not Data Available
  • On 3/11/2020 CEO Harlan Waksal Buy 12,600 at average price of  $3.48 with total value of : $43,848.00

What other brokers have to say about Kadmon :

  • 6/4/2020 – Kadmon was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $5.25 price target on the stock.
  • 6/2/2020 – Kadmon was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating.
  • 5/28/2020 – Kadmon was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $5.25 price target on the stock.
  • 5/26/2020 – Kadmon was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating.

Other firm’s rating by HC Wainwright:

  • 6/29/2020 – Chiasma had its price target raised by analysts at HC Wainwright from $10.00 to $11.00. They now have a “buy” rating on the stock.
  • 6/29/2020 – Novavax had its price target raised by analysts at HC Wainwright from $50.00 to $101.00. They now have a “buy” rating on the stock.
  • 6/29/2020 – Gossamer Bio is now covered by analysts at HC Wainwright. They set a “buy” rating and a $31.00 price target on the stock.
  • 6/29/2020 – Arena Pharmaceuticals is now covered by analysts at HC Wainwright. They set a “buy” rating and a $90.00 price target on the stock.

See More Analyst Rating at: RATING